A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453

NCT02052687 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: LFX453 H1
DRUG: LFX453 L1
DRUG: LFX453 H2
DRUG: LFX453 L2
DRUG: Imiquimod
DRUG: Placebo 1
DRUG: Placebo 2

Sponsor

Novartis Pharmaceuticals